A proposed class-action lawsuit has been filed in federal court against Dr. James Curtis Roberson II, a 63-year-old rheumatologist who spent years treating patients in Maryland and Virginia. On April 17, 2026, Basham v. MedStar Health, Inc. was filed in the U.S. District Court for the District of Maryland. Roberson and MedStar are both named, and the plaintiffs’ lawyers claim that the class could easily exceed 100 patients. Although one of the lead lawyers, Philip Federico, has stated that the size of the class will depend on how it is defined, the damages sought exceed $5 million.

The named plaintiff is LaShawn Basham. She started seeing Roberson at the MedStar Orthopaedic Institute in Brandywine in 2021 or 2022, seeking assistance in treating Sjögren’s syndrome, an autoimmune disease that results in excruciating pain and exhaustion. The complaint claims that what started out as doctor’s appointments became something completely different. repeated examinations of the breasts for no medical reason. lotion-based full-body massages. According to the filing, inappropriate touching was done “under the guise of medical assessment.” According to the complaint, Basham first thought the tests were essential. It’s difficult to sit with that part. Doctors must be trusted by their patients.

Before the civil lawsuit began, the Maryland Board of Physicians had already developed a case against Roberson. Early in 2025, he was placed on suspension, and by January, he had agreed to have his Maryland medical license permanently revoked. Virginia came next. Roberson denied the most serious accusations made during his testimony under oath, but he acknowledged that he “lost his way.”

Beginning around 2022, he admitted to sending flirtatious emails, having romantic relationships with four patients, and witnessing the erosion of his own boundaries. Federico told reporters, “He was obviously doing it for self-pleasure.” “It got to the point where he couldn’t restrain himself.”

For its part, MedStar Health has exercised caution when making public remarks. After a patient came forward, the organization suspended Roberson in October 2024, fired him following an internal investigation, and then reported him to the state board in November of the same year. MedStar promised in a statement that it would “never tolerate inappropriate behavior” by its providers and expressed gratitude to the patients who came forward. In situations like this, every hospital system employs this kind of language. It’s another matter entirely whether it can withstand the scrutiny of discovery. The lawsuit claims that MedStar disregarded warning indicators, such as that advisory letter from 2018, and the plaintiffs will probably put a lot of pressure on what the system knew and when.

Federico has dealt with similar situations in the past. He represented patients of the late Johns Hopkins gynecologist Nikita Levy and victims of Delaware pediatrician Earl Bradley, two cases that profoundly affected the local communities. Although cooperation in the early stages of litigation can mean different things, it is noteworthy that he has described MedStar as cooperative thus far.

It is more difficult to forecast how this case will change the discourse surrounding institutional oversight. As this develops, it seems as though the most difficult questions aren’t related to any one physician. They are about the paperwork, the systems, the warnings that are filed and then forgotten, and the patients who wondered for years if what transpired in those rooms was typical.

The post Inside the Dr. James Curtis Roberson Lawsuit: How Over 100 Patients Say a Trusted Doctor Crossed the Line appeared first on Creative Learning Guild.

A 2.8% cost-of-living adjustment for 2026 was announced by the Social Security Administration. On paper, that meant the average retiree would receive an additional $56 per month, increasing their average benefit from roughly $2,015 to $2,071. It’s the kind of figure that seems comforting until you compare it to what Medicare actually charged beginning on January 1.

Medicare Part B premiums, which the majority of retirees pay each month for physician and outpatient coverage, increased by $17.90 to $202.90 from the prior year. Compared to a COLA of 2.8%, that represents a 9.7% increase in just one year.

In short, Part B premiums are increasing nearly three and a half times faster than the adjustment intended to shield retirees from inflation, according to Mary Johnson, a Social Security and Medicare policy analyst. Before a single dollar ever made it into a beneficiary’s bank account, that $17.90 monthly premium increase consumed almost a third of the total COLA increase.

Watching this unfold year after year gives the impression that the headline figure and the actual retirement income are two different things. The $56 increase is revealed. The $17.90 clawback is discreetly taken out of the Social Security check prior to its issuance. The majority of retirees who use direct deposit are unaware that the subtraction is taking place. Sometime in February, they finally realize that things aren’t quite as cozy as the news had promised.

The math becomes much more difficult for retirees with higher incomes. Those subject to IRMAA surcharges — individuals earning above $109,000 or couples above $218,000 — face premium increases that can absorb 50% to 72% of the COLA adjustment entirely.

A person in the first IRMAA tier, whose monthly Part B premiums were about $284, saw that amount increase by about $25 in 2026, using half of what the COLA provided. The math shows how vulnerable fixed-income households are to healthcare cost inflation in particular, even though it’s possible that many of these retirees are financially secure enough to absorb it.

The numbers from a single year don’t fully capture the structural issue. The CPI-W index, which measures expenses for urban wage earners rather than retirees, is used to compute Social Security’s COLA. Higher inflation estimates are consistently produced by an experimental index known as CPI-E, which was created to reflect the real spending patterns of older Americans who spend more on housing and healthcare.

The COLA would have probably been between 3.0% and 3.2% in 2026 if CPI-E had been used. For the duration of a retiree’s life, that half-percentage-point difference adds up to about $10 more each month. On paper, it’s a fairly minor fix. It’s a significant one that spans ten years.

The “hold harmless” clause is one significant safeguard hidden within the regulations. This provision states that a retiree’s Part B premium increase cannot be greater than their COLA raise. The premium is capped at $15 if the COLA increases your monthly check by $15 and the premium would otherwise increase by $18. It keeps the most vulnerable recipients from truly losing ground in terms of absolute dollars, but it doesn’t address the underlying squeeze. This cap benefits an estimated one million people annually.

However, the overall picture is one of gradual deterioration. Retirees on fixed incomes feel the tightening more keenly than most, as the national personal savings rate has dropped to about 4%. At 56.6, the University of Michigan Consumer Sentiment index is significantly below the threshold that denotes true financial optimism.

The difference between a $56 raise and a $32 net gain is significant for someone who depends on Social Security to pay their monthly expenses. The bill is for utilities. It’s a copay. It’s the silent math of surviving.

It’s difficult to ignore the tendency for the COLA percentage to dominate policy discussions, while the Medicare premium increase is announced separately, weeks later, and receives much less public attention. The two have a close relationship. Before assuming that the new year brought significant relief, anyone who depends on Social Security income should compare the two figures because the money that actually arrives and the headline figure are rarely the same.

The post Social Security COLA vs Medicare: Why Your “Raise” Isn’t Really a Raise appeared first on Creative Learning Guild.

There are two violations. Two summers in a row. About 2.8 million people are impacted. The $14 million class action settlement that McLaren Health Care Corporation, commonly known by its initials, MHCC, agreed to settle, with claims open through April 29, 2026, is based on that sequence.

Judge B. Chris Christenson is presiding over the case, officially named Cindy Womack-Devereaux, et al. v. McLaren Health Care Corporation, at the 7th Judicial Circuit Court in Genesee County, Michigan. Flint, the county seat, has spent years navigating institutional failures affecting the health and safety of its citizens. According to the lawsuit, MHCC neglected to put in place sufficient cybersecurity measures, which gave hackers access to private patient data on both occasions. In a pattern that has become well-known in healthcare data breach litigation, MHCC has denied any wrongdoing but consented to the settlement to settle the claims without a trial.

The $14 million settlement includes a credit monitoring benefit in addition to two primary payment tracks. Up to $5,000 is available to class members who can provide proof of actual out-of-pocket losses related to the breaches, such as fraud charges, identity theft remediation costs, credit repair expenses, and up to five hours of lost time at a rate of $25 per hour. Bank statements, receipts, or other contemporaneous proof are needed for that high end. The second track, which is accessible to all members of the settlement class without the need for documentation, is a pro rata cash payment taken from the settlement fund’s remaining balance following the payment of documented-loss claims. The total number of valid claims will determine the final per-person amount under that option; it may be small, but for the majority of class members, it’s the accessible route.

When assessing what a settlement like this actually does for impacted patients, it is important to recognize that healthcare data is fundamentally different from other types of personal information that are compromised. It is possible to cancel your credit card number. You can’t use your Social Security number. Your insurance policy numbers, diagnoses, and medical history are all permanent records that will follow you for the rest of your life. The exposure doesn’t end once that information starts to circulate through the markets where stolen data is bought and sold. According to financial advisor Kevin Thompson, who was cited by Newsweek, the payout is frequently “pennies on the dollar compared to the damage caused.” He’s not incorrect. However, the settlement also mandates that McLaren fortify its data security systems and sustain those enhancements for a minimum of two years—a forward-looking component that is simple to ignore in the emphasis on monetary sums.

It’s difficult to ignore how consistently this pattern occurs in the healthcare industry. A class action is filed, a settlement is negotiated, millions of patients receive notification letters, a hospital network is compromised, and so on. Similar settlements involving health systems, insurance companies, and pharmacy chains have been announced more frequently over the past few years, so the McLaren hack isn’t the only one. The fact that the same organization experienced it twice in a 12-month period sets the MHCC case apart. The court documents detail illegal access during two distinct, almost parallel windows in successive summers, implying that the vulnerabilities that allowed the first breach had not been completely fixed prior to the second one.

The next steps are simple for anyone who received a notification letter from McLaren Health Care in 2023 or 2024. Class members who have their individual Notice ID and confirmation code can file online in a matter of minutes after the settlement website went live. To confirm eligibility, those who think they were impacted but never got a formal notice can get in touch with the settlement administrator. The deadline for filing claims is April 29, 2026, and as with all class actions, failure to do so will result in the loss of both the benefits and the ability to file a separate lawsuit for the same claims.

The Genesee County courthouse at 900 Saginaw Street in Flint was to host the final approval hearing on April 21, 2026. Although preliminary approval was given in December 2025 and no major objections seem to have derailed the process, it remains to be seen whether the settlement is ultimately approved and what the distribution timeline looks like after that. The next few weeks are crucial for the 2.8 million people who are awaiting word from a Michigan court regarding the value of their compromised medical records.

The post MHCC Class Action Settlement: 2.8 Million Patients Had Their Data Stolen — Twice. Here’s How to Claim Your Share of $14 Million. appeared first on Creative Learning Guild.

This is one of the reasons why the current settlement is more difficult to accept than a standard class action.

After inspecting the Tom’s manufacturing facility in Kennebunk, Maine, the FDA sent a warning letter to Tom’s of Maine and its parent company in late 2024. Inspectors discovered particular and disagreeable things. a black, mold-like material behind a water storage tank and at the base of a hose reel. powder residue next to a container of children’s toothpaste, Tom’s Silly Strawberry Anticavity. The organization came to the conclusion that some of the facility’s operations did not adhere to FDA Current Good Manufacturing Processes. After reviewing pre-release testing data, Tom’s concluded that about 4,900 impacted toothpastes did not present a risk to consumer safety. Nevertheless, a lawsuit was filed in November 2024, claiming that the company had used dishonest and misleading business practices in the production, promotion, and distribution of its toothpaste products.

The resulting settlement, Rabinowitz et al. v. Colgate-Palmolive Company, et al., gives qualified US consumers $2.9 million. The claims have been refuted by Colgate-Palmolive. Instead of going to trial, the company decided to settle the dispute through a fund that any eligible customer can access before July 6, 2026. This decision carries no legal admission of wrongdoing.

Tom’s of Maine Settlement: $2.9 Million, an FDA Inspection, and a July 6 Deadline You Should Not Miss

The window of eligibility is wide. A claim may be made by any US customer who bought any toothpaste from Tom’s of Maine between November 21, 2020, and March 6, 2026. That includes purchases of the entire Tom’s toothpaste line, not just particular flavors or formulations, for about five and a half years. The procedure is made to be easily accessible. You are eligible for a complete reimbursement of your purchase, up to a maximum of three items, if you have an invoice, receipt, or loyalty record from a retailer that attests to your purchase. You can still file and get the average manufacturer’s suggested retail price for one product per household even if you have absolutely no proof of purchase. Every approved claim will result in some financial relief, according to the settlement administrators; the fund won’t just pay out nothing if there aren’t many claims.

This case has a texture that is worth pondering for a while. The foundation of Tom’s of Maine’s brand was its ability to provide consumers who read labels, were concerned about the origins of ingredients, and sought assurance that the products they were brushing on their teeth twice a day were made ethically and cleanly. In contrast to a data breach or a fee dispute, the FDA inspection findings—mold-like substances, powder residue, manufacturing process issues—directly violate that promise. The internal review’s conclusion that there is no safety risk might be correct. However, no settlement language completely closes the gap between the brand’s positioning and the physical conditions detailed in federal inspection documents.

Tom’s is by no means the first clean-label or natural brand to come under this kind of scrutiny. Over the years, the organic and natural food and personal care industries have produced a substantial body of litigation, much of which focused on the discrepancy between product reality and marketing language. Numerous supplement companies, Whole Foods, and several cosmetics brands have all experienced similar challenges. When the brand’s core identity—the reason consumers chose it over less expensive options—is being questioned, it tends to differentiate the cases that elicit a significant consumer response.
This settlement’s payments won’t be made right away. Distributions cannot start until the final approval hearing is held on September 10, 2026, and any appeals could cause the deadline to be further extended.

Anyone who meets the requirements is advised to file by the deadline of July 6th and then wait. Claims may be filed online via the settlement website or by printing and mailing a form to the Portland, Oregon class administrator. Depending on your preferences, you can pay with a physical check, PayPal, Venmo, or Zelle. The nonprofit organization Equal Justice Works, which focuses on public interest law, will receive any settlement money that is not claimed after distribution.

Going forward, the image of Tom’s of Maine toothpaste on a pharmacy shelf—the simple logo, the earthy colors, and the promises prominently displayed on the tube—will probably remain the same. The brand is still in existence. The goods are still available. However, observing this settlement’s legal journey serves as a reminder that a facility’s reality and a label’s claims don’t always align, and that customers who paid more for one should be informed about the other.

The post Tom’s of Maine Settlement 2026: $2.9 Million Payout and a July 6 Deadline Every Toothpaste Buyer Should Know appeared first on Creative Learning Guild.

On February 4, 2026, Christina Anstett, a mother, filed the lawsuit, Anstett v. Ferrara Candy Company, in the Northern District of Illinois. Anstett claims that she frequently bought Ferrara products and gave them to her young child. The 38-page complaint is based on independent laboratory testing carried out by the state of Florida as part of a larger initiative to create “clean and transparent food systems.” To put it mildly, the results of Florida’s lab’s testing of samples from ten distinct Ferrara candy varieties that were bought at typical retail establishments were not what a candy company wants to be reported in a federal filing. According to the lawsuit, eight out of ten products tested positive for toxic levels of arsenic. The worst offenders were Banana Laffy Taffy, where four pieces allegedly exceed the same threshold, and Sweet Tart Ropes, which the complaint claims exceed an entire year’s recommended arsenic exposure in less than half a package.

Nerds Class Action Lawsuit: The Candy Your Kids Eat Every Day May Contain Toxic Levels of Arsenic

There hasn’t been a recall from Ferrara, which is owned by the massive Italian confectionery company Ferrero and sells its goods at almost all of the major American retailers. The results of Florida’s testing program have been refuted by the National Confectioners Association, which bills itself as the biggest candy trade association in the nation. The company’s stance is that there isn’t an emergency, at least as suggested by the absence of any product withdrawals. It’s still unclear if Ferrara’s confidence stems from a calculation that the legal and PR costs of a recall would be greater than challenging the claims in court, or if it is based on science that Ferrara hasn’t yet made public. Businesses in comparable circumstances have previously placed that wager, sometimes with success.

The nature of the contaminant itself makes it especially hard to ignore the arsenic allegation. Arsenic is not a manufacturing byproduct that was inadvertently spilled into a sugar syrup vat. Regulators have long known that this naturally occurring heavy metal builds up in some food categories and enters food systems through contaminated soil, water, and agricultural inputs. Both the American Academy of Pediatrics and the FDA have identified arsenic as hazardous to children at any significant exposure level. It is categorized as a known human carcinogen by the WHO. According to the complaint, Ferrara not only neglected to check for the presence of arsenic but also neglected to disclose it, selling goods to a market that it knew was primarily made up of children based on the packaging’s design.

The final point is the one that persists. Ferrara’s candy brands are sold in bright, cartoonish packaging with whimsical names, according to the lawsuit, which also claims the company is well aware that children are its main target market. That framing is especially unsettling because it eliminates any doubt about who is most at risk if the arsenic findings hold up under scrutiny, which is not surprising given that candy companies have always marketed to children. In recent weeks, parents who have read the comment sections on lawsuit tracking websites have reported experiencing vertigo, nausea, stomach pain, and ER visits. They have linked these symptoms to their candy consumption in anecdotal ways that are difficult to completely discount when the underlying lab data is located in a federal court filing.

Due to its candy lineup, Ferrara has previously been the target of a class action lawsuit. A different lawsuit filed in 2019 claimed that the company had misrepresented the absence of artificial flavors in Nerds, Runts, and Everlasting Gobstoppers while actually using synthetic malic acid. After a settlement, the case was willingly dismissed. The current lawsuit comes at a time when consumer awareness of heavy metals in food has been growing for years, partly due to broader findings about arsenic in rice, baby food, and fruit juice that garnered significant regulatory and media attention throughout the early 2020s. The lawsuit is much more serious in terms of its potential health implications.

Every American consumer who bought Black Forest Gummy Bears, Laffy Taffy, NERDS, Sweet Tarts, Sweet Tarts Ropes, or Trolli products at any time during the relevant statute of limitations is included in the lawsuit’s broad definition of the class. The plaintiff claims that customers paid more for goods they would not have purchased if they had known about the arsenic content, and they are requesting actual damages, restitution, disgorgement of profits, and legal fees.

Observing all of this, it seems like this case is coming at a time when consumers and judges are growing impatient with the discrepancy between what food is advertised and what it truly contains. The courts will have to decide whether the Florida testing methodology can withstand the scrutiny that Ferrara’s legal team will unavoidably apply to it. However, the candy is still on the shelves because no recall has been issued while the lawsuit moves through the legal system. Parents continue to purchase it. Children continue to eat it by the handful, and the businesses involved are still awaiting a judge’s ruling.

The post Nerds Class Action Lawsuit: The Candy Your Kids Eat Every Day May Contain Toxic Levels of Arsenic appeared first on Creative Learning Guild.

Customers Jennifer Williams and David Strauss filed the lawsuit, Williams, et al. v. Starbucks Corp., on January 13, 2026. Hagens Berman, one of the nation’s most active consumer protection firms, represented them. There are two separate threads to the complaint, each of which is uncomfortable in a different way. The first challenges Starbucks’ sourcing claims, claiming that the company’s C.A.F.E. Practices certification program—the foundation for all those “ethical sourcing” labels—has been used for years on farms that were concurrently found to be committing grave human rights violations by labor advocates, governments, journalists, and United Nations agencies. Workers are allegedly coerced into hazardous situations without wearing protective gear. Housing is deemed unacceptable. local labor law infractions. All on farms bearing the Starbucks ethical sourcing seal. According to the lawsuit, Starbucks refused to reveal any corrective action it was taking after being made aware of these infractions.

Key Information Table

The second thread is more visceral right away. Three volatile organic compounds—methylene chloride, benzene, and toluene—were found in independent testing of Starbucks’ decaf house blend medium roast coffee at levels the lawsuit claims surpass EPA safety regulations. At 22 parts per billion, methylene chloride—a chemical that the EPA deems dangerous for ingestion at any concentration—was found. The amount of benzene, which the World Health Organization and the EPA both recognize as a human carcinogen, was 28 parts per billion, or 23 parts per billion, above the EPA’s safe threshold. According to the lawsuit, toluene, at 87 parts per billion, is not permitted as a food ingredient or processing aid under U.S. regulations and is more frequently linked to industrial manufacturing, adhesives, and paint thinners than with anything you’d expect to find in a drink ordered at a coffee counter.

The decaf accusation is especially confusing. Customers who purchase decaffeinated coffee frequently do so due to health concerns, such as caffeine sensitivity, medical advice, or pregnancy. Chemical solvents may be used in the decaffeination process itself, and the lawsuit contends that the testing results show residue from that industrial process that was never disclosed to customers. The complaint contends that Starbucks’ “100% Arabica coffee” claim deceives consumers into thinking they are purchasing a simple, pure product, but independent testing indicates the reality is more nuanced than that label suggests.
Starbucks retaliated. According to a company representative, the accusations are “inaccurate” and Starbucks regularly audits farms, keeps an eye on its supply chain, and responds to infractions. Although it makes sense from a legal strategy perspective, the company’s initial response did not address the specific chemical testing data, leaving the fundamental scientific question unanswered in any significant public way. The methodology employed by the plaintiffs’ independent testers may be contested during discovery, or the company’s own testing may produce different results.

It’s important to put this case in perspective as we watch it develop. Starbucks has previously faced legal scrutiny. After years of legal wrangling, a different judge dismissed the 2018 California case that sought warnings about acrylamide, a natural byproduct of roasting coffee beans. The case was dismissed in 2020. The nature of the current lawsuit is different. It concerns purported industrial chemical residue from decaffeination and sourcing claims that the plaintiffs contend have been refuted by documented evidence for a full decade, rather than a naturally occurring byproduct of the roasting process. It is much more difficult to write this off as fear mongering when those two accusations are combined.

The case is still pending. On legal tracking websites, there have been over 1,100 comments from customers asking to join the class. In the end, the Seattle trial court will decide whether the accusations are true, whether the class is certified, and what information is revealed about Starbucks’ internal knowledge of its decaffeination chemistry and supply chain conditions. For the time being, the lawsuit has raised an issue that won’t go away: what precisely does a business owe the customers who trust it when it prints an ethical pledge on each bag it sells?

The post The Starbucks Class Action Lawsuit Claims Your Decaf Coffee Contains Paint Thinner Chemicals appeared first on Creative Learning Guild.

What followed was a lawsuit that could change how clinics and hospitals around the nation consider using AI tools in exam rooms, depending on how the courts resolve it. One of the biggest health systems in Southern California, Sharp HealthCare, and a number of its affiliated medical groups are named in the complaint, which was submitted to San Diego Superior Court in November 2025. Abridge, a Pennsylvania-based company whose platform records patient-provider conversations, creates a transcript, and uses that audio to draft clinical notes for doctors to review and sign, is the AI tool at the heart of the case. More than 200 major health systems, including Johns Hopkins and the Department of Veterans Affairs, currently use Abridge’s technology. There are a lot of exam rooms there. Furthermore, it appears from this instance that some of them didn’t stop to figure out the consent piece before activating the microphones.

It is worthwhile to examine the mechanics of what is said to have occurred because they provide insight into how quickly these tools were adopted and how slowly the paperwork caught up. The complaint claims that without Saucedo’s knowledge, a clinician’s microphone-enabled device recorded the audio of his visit and sent it to Abridge’s cloud system, where it was processed and used to create a clinical note. When Saucedo later got in touch with Sharp to ask for the recording to be deleted, he was informed that the vendor keeps audio for about 30 days and that the file couldn’t be deleted right away. Instead, Sharp allegedly offered to edit or remove the AI-generated note, which is not exactly the same as erasing the recording.

Key Information: Sharp HealthCare AI Scribe Lawsuit

Regarding this, California’s privacy law is clear. All parties must give their consent before recording a private conversation in accordance with the California Invasion of Privacy Act. Not implicit consent. Not consent tucked away in the intake documents. Everyone involved. In addition to failing to get that consent, the complaint claims that Sharp added boilerplate language to patient charts that claimed patients had been informed and had given their consent. The plaintiff calls this language blatantly false. More so than the recording itself, that particular detail may be the most detrimental aspect of the filing. A violation of compliance occurs when consent is not obtained. It is quite another to record consent that never occurred.

It’s difficult to ignore the fact that three months prior to Saucedo’s visit, in April 2025, Sharp announced its collaboration with Abridge. By any reasonable interpretation, the rollout seems to have proceeded more quickly than the infrastructure for consent required to support it. Sharp is not the only one with that pattern. AI documentation tools have been enthusiastically embraced throughout the healthcare industry due to actual issues like physician burnout, documentation burdens, and the amount of time clinicians spend staring at screens instead of patients. Businesses like Abridge make a strong case, and when done correctly, the outcomes appear to be significant. In 2024, UW Health in Madison, Wisconsin, started testing the technology. Since then, they have released an open-source implementation guide that covers precisely the consent procedures that Saucedo’s case seems to have lacked. When a patient had reservations, a family medicine doctor there talked about stopping the recording in the middle of the visit, describing it as empowering for the patient. It’s not difficult. However, before the device is put in the pocket, someone must create the workflow.

Any Californian who had a medical visit with a Sharp provider that was recorded without consent on or after April 1, 2025, is covered by the lawsuit’s request for class-action certification. There may be more than 100,000 patients in the potential class. The statutory damages under CIPA, which are $5,000 for each infraction, make the math sobering for health systems and, to be honest, for any company that interacts with customers and uses voice-activated AI. The legal theories in this case—unauthorized recording, improper third-party access, false consent documentation, and inadequate deletion workflows—are not unique to the healthcare industry, according to law firms monitoring what is known as “digital wiretapping litigation.” Using call-center AI, chatbot summarization, or conversation analytics exposes retailers, financial services firms, and hospitality brands to the same structural risks. The consequences are felt most keenly in the exam room.

According to David Simon, an associate professor of law at Northeastern University School of Law, cases like this one must navigate current privacy and consumer protection laws because states and the federal government have been slow to develop AI-specific disclosure requirements for medicine. There is a real gap that cuts both ways. Health systems are left to interpret California’s all-party consent law as best they can in the absence of clear federal regulations. Some take great care. Others seem to move quickly and believe the advantages of the technology will outweigh the administrative burden of actually informing patients about their conversations.

Sharp has stated that patient safety and privacy continue to be organizational priorities while declining to comment on the details of the lawsuit. Abridge has not addressed the accusations in public. Whether the class will be certified or how the courts will ultimately decide are still up in the air. However, the lawsuit has already made the public face a question that ought to have been raised before the first microphone was turned on. The expectation of privacy is not a technicality in a doctor’s examination room, where people say things they don’t say anywhere else. That’s the whole idea.

The post Sharp HealthCare Sued Over AI Scribe Tool and Blatant Lack of Patient Consent appeared first on Creative Learning Guild.

A joint editorial published by more than 200 of the world’s top medical journals, including The Lancet, The New England Journal of Medicine, and the British Medical Journal, made clear what the medical community had been working toward for years: climate change is the biggest threat to public health worldwide. not a cardiac condition. not a communicable illness. Not even a pandemic in the future. Every inhabited continent’s healthcare systems are already being strained by climate change, which is already occurring and killing people. The scope of the editorial was unheard of. There is no comparable moment in the history of medical publishing where so many journals, representing so many specialties and so many countries, aligned behind a single statement about a non-clinical threat to health. Just that fact merits more consideration than it has gotten.

IMPORTANT INFORMATION TABLE — CLIMATE CHANGE & GLOBAL PUBLIC HEALTH

The health effects reported in the journals are not estimates. They are the reality of the present, growing annually. Over the past 20 years, the number of heat-related deaths among adults over 65 has increased by more than 50%. This increase can be attributed to both an aging global population that is physiologically less able to regulate body temperature during prolonged nighttime heat and more frequent and intense heatwaves. Since 2010, this trend has been documented in the Lancet Countdown report, which tracks climate-health data annually. A statistical model is not necessary for doctors treating patients with heat exhaustion, asthma flare-ups brought on by wildfire smoke, or diarrheal illness from contaminated water sources in emergency rooms from Fresno to Karachi. They are keeping an eye on it throughout their patient lists.

The geography of disease is also evolving, and it is doing so more quickly than public health infrastructure can keep up. In the past, dengue, chikungunya, and other vector-borne disease-carrying mosquito species were mostly found in tropical latitudes. These insects are spreading northward as temperatures rise, into areas where neither the public health system nor the population has developed any significant immunity or readiness. The chief editor of the New England Journal of Medicine talked about witnessing this change in real time, with illnesses that were problems in Central and South America ten years ago now needing medical care in some areas of the United States. That is not a risk for the future. That is the state of diagnostics today.

Who suffers the most from this is particularly cruel. The WHO data is clear: during the past ten years, the death rate from extreme weather events was fifteen times higher in the world’s most vulnerable regions than in less vulnerable ones. The worst health effects of these changes are being felt by the communities that contribute the least to the greenhouse gas emissions that are causing them. Rural communities lacking climate-resilient health infrastructure, low-income nations in South Asia and sub-Saharan Africa, and small island developing states are all already dealing with issues that wealthier regions are still primarily considering for the future. Every year, health shocks that are unaffordable force about 100 million people into poverty, and climate change is increasing the frequency of these shocks as well as the expense of recovering from them.

The extent to which this medical consensus has failed to advance policy at the rate required by the evidence is difficult to ignore. The journals specifically compared climate change to COVID-19, pointing out that the pandemic ultimately mobilized the same level of urgency, funding, and coordination, as well as a willingness to reorganize traditional priorities. Naturally, the distinction is that a pandemic manifests acutely and visibly, with a particular pathogen and a measurable death toll appearing in a matter of weeks. Because the health effects of climate change are dispersed across a thousand presenting conditions and a hundred distinct causal pathways, it is simple for institutions to classify each individual crisis under the category that seems most urgent rather than identifying the underlying cause.

The medical journals also examined healthcare in general. Approximately four to five percent of greenhouse gas emissions worldwide are caused by health systems, which makes them a significant contributor to the issue they are currently being asked to address. The editorial urged health systems to achieve net zero by 2040, which is both a realistic objective and a significant logistical challenge for organizations already facing staffing and budgetary constraints. The process of decarbonizing the healthcare industry may serve as a model for other industries, proving that intricate, operationally crucial systems can make the shift without sacrificing the services they offer. It’s also possible that most health systems will postpone that change indefinitely in the absence of persistent outside pressure.

In the end, the more than 200 journals were stating in the most authoritative collective voice that modern medicine has ever used to address a policy issue that this is not an issue of competing priorities, a future problem, or a peripheral concern. The waiting areas are already filled with patients. The wards are already full. New regions are already being affected by the diseases. Deaths are already taking place. The editorial’s conclusion was clearly a diagnosis rather than an obituary, as one of its editors put it. In medicine, a diagnosis also marks the start of a course of treatment. It is quite another matter entirely whether those who have the power to prescribe one are paying attention.

The post Climate Change Is Now the Biggest Threat to Global Public Health, 300 Medical Journals Agree appeared first on Creative Learning Guild.

Ozempic’s active component, semaglutide, is an agonist of the GLP-1 receptor. It imitates the natural hormone glucagon-like peptide-1, which controls hunger and blood sugar. The medication slows the rate at which food leaves the stomach, prevents the liver from releasing extra glucose into the bloodstream, and increases the release of insulin from the pancreas when blood sugar levels rise. The majority of the symptoms that people experience when they first take the medication are caused by this final mechanism, which is slowed gastric emptying. In addition to keeping you feeling full and stabilizing blood sugar, the stomach’s longer meal processing time also sets the stage for the side effects that dominate most discussions about Ozempic.

Key Information: Ozempic (Semaglutide)

Reference Links: Ozempic Official Side Effects Page — Novo Nordisk Ozempic Side Effects — WebMD

Depending on the study and dosage, 15% to 53% of users experience nausea. 8% to 35% of people experience diarrhea. The most frequent complaints include cramping in the abdomen, vomiting, and constipation. These numbers are all substantial. In actuality, this means that a significant percentage of individuals who begin taking Ozempic spend the first few weeks coping with some form of gastrointestinal discomfort, such as eating smaller meals, avoiding fried food, keeping crackers and clear liquids on hand, and waiting for their body to adjust before deciding the medication isn’t worth it. The majority of clinical guidelines indicate that it does adjust, usually in a few weeks, especially if the recommended dose escalation schedule is carefully followed rather than jumping to higher doses.

Then there are the more peculiar experiences that aren’t always included in the list of typical adverse effects. Technically known as sulfur burps, “ozempic burps” are brought on by the accumulation of sulfur compounds in the stomach as digestion slows. Cutting back on high-sulfur foods like broccoli, garlic, and red meat is the solution, but those foods cannot be completely avoided. They also have an unpleasant taste and odor. Some people manage them with probiotics, ginger tea, and over-the-counter digestive aids. A smaller but significant portion of users also experience acid reflux, headaches, exhaustion, and dizziness, especially during the first few weeks of treatment.

The more significant risks should be taken into consideration without being overstated. A small number of Ozempic users have been reported to have pancreatitis, or inflammation of the pancreas, primarily in those with a history of the condition. In rare instances, the stomach essentially stops moving food forward at all, a condition known as gastroparesis, a more severe version of the slowed digestion the medication typically causes. At least 20 intestinal blockage cases, including two fatalities, have been reported to the FDA. As a result, Novo Nordisk is required to update its warning label to indicate the risk. The FDA mandates that the medication include a warning for anyone with a personal or family history of medullary thyroid carcinoma. Thyroid tumors have been observed in animal studies; it is unclear whether they occur in humans at significant rates. These dangers do exist. They are uncommon. However, they are genuine enough to discuss candidly with a prescribing doctor, particularly for patients with pertinent medical histories.

he findings of a massive new study on mental health are the most unexpected recent development in the Ozempic story. Semaglutide users were 44% less likely to suffer from depression, 38% less likely to develop anxiety disorders, and 42% less likely to be hospitalized for mental health conditions than those taking other diabetes and weight-loss medications, according to research involving nearly 100,000 participants. Substance-related hospitalizations decreased by 47%. These are significant figures. The mechanism could be partially attributed to decreased alcohol intake, enhanced body image after weight loss, improved glycemic control, or direct effects on the brain’s reward and dopamine systems, but the researchers were unable to fully explain it. Regardless of the reason, the results imply that Ozempic’s effects go far beyond the gut in ways that researchers are still trying to figure out.

Additionally, there are gender-specific factors that should be given more consideration than they usually are. Because Ozempic’s effects on obesity and metabolic function can restore ovulation in women who had irregular cycles or weren’t ovulating at all, women taking the medication have reported unintended pregnancies. Ozempic’s effects on digestion may interfere with the absorption of contraceptives, as some pregnancies have been reported in women using hormonal birth control. The medication should be stopped at least two months prior to a planned pregnancy, according to Novo Nordisk. Although not specific to Ozempic, the cosmetic effects—loose skin on the face, body, and chest as a result of rapid fat loss—tend to be more noticeable with medication-assisted weight loss than with slower dietary approaches.

It’s difficult to ignore the fact that the public discourse surrounding Ozempic frequently veers between two extremes: it’s either a miracle medication or a risky short cut. Compared to either version, the clinical picture is more complex. The risks are controllable with proper medical supervision, and the documented benefits are significant for many individuals with type 2 diabetes, cardiovascular risk, or chronic kidney disease. The risk calculation is different for individuals who use compounded versions without a prescription or who take doses that are not appropriate for their health. The medication clearly calls for a genuine discussion with a doctor who is familiar with the patient’s entire medical history, not a prescription based on a popular hashtag.

The post New Study Reveals Surprising Ozempic Side Effects That Have Nothing to Do With Your Stomach appeared first on Creative Learning Guild.

“Together for health” is this year’s theme. “Stand with science” has a weight that wasn’t quite necessary for earlier themes. With this campaign, the WHO is not only commemorating scientific advancements. It’s protecting it. The call to stand with science is less a celebration than a counteroffensive in a world where false information spreads more quickly than peer-reviewed research can respond, where anti-vaccine sentiment contributed to avoidable deaths during the COVID-19 pandemic, and where a nation like Pakistan is still one of only two places on earth still dealing with endemic polio. It’s not a subtle observation. It’s the current state of affairs.

This year’s campaign’s anchor events are truly important. Under its G7 presidency, France hosted the International One Health Summit, which united experts in the fields of health, animals, and the environment around the idea that human health is inextricably linked to the health of ecosystems and animal populations. Alongside it, almost 800 scientific institutions from over 80 countries came together for the first Global Forum of WHO Collaborating Centers, creating what WHO calls the largest scientific network ever gathered around a UN agency. Watching researchers from five continents’ worth of institutions compare notes on zoonotic diseases and antimicrobial resistance while standing in the corridors of a summit that size is the kind of moment that makes the theme feel less like a catchphrase and more like something that is actually being built.

Because so many of the health emergencies of the last 20 years—including SARS, H1N1, COVID-19, and a number of others that are still being closely monitored—began at the border between human and animal populations, the One Health framework is important. Without institutional momentum, it is extremely difficult to maintain the kind of cross-disciplinary, cross-border collaboration needed to address that boundary. Part of the goal of the 2026 campaign is to create that momentum while political will is still present, before governments feel comfortable pulling back from multilateral health commitments due to COVID-19.

Observing the social media reaction to this year’s World Health Day gives the impression that it was received differently than previous themed days. Pakistan’s Prime Minister Shehbaz Sharif urged the expansion of digital health and evidence-based health policy. Narendra Modi of India wrote on social media about bolstering healthcare systems. The Maldives explained how their national health strategy directly incorporates scientific knowledge. At a time when doing so isn’t widely accepted, these government officials are openly supporting science. Another, more crucial question is whether the speeches result in budgetary allocations. However, the alignment of rhetoric is important.

Access is the more difficult topic of discussion, which tends to soften on days like these. Less than 1% of Pakistan’s GDP is allocated to healthcare. Its neighbor, Bangladesh, spends more than twice that amount. About half of Pakistanis do not have access to basic primary healthcare. Adolescent diabetes is on the rise at rates that should be concerning but are instead dismissed as a side issue. Approximately 19 million people in Pakistan suffer from undiagnosed hypertension. Campaigns to raise awareness do not alone improve these statistics. They call for consistent public funding at a level that the majority of developing-nation governments have not yet committed to.

The tension at the core of the idea of World Health Day is difficult to ignore. It calls for equal collaboration between some of the world’s most cutting-edge scientific institutions and some of the world’s most underfunded health systems. In theory, everyone has access to the knowledge. The distribution of funding, infrastructure, skilled workers, and supply chains is highly unequal. When diagnosing the interdependence of environmental, animal, and human health, the WHO’s One Health approach is accurate. Every year on April 7, the question of whether the political and economic systems required to address that diagnosis can be constructed in time is raised, but it is never fully resolved.

The best thing World Health Day does is generate a moment of public awareness that might not otherwise occur. Health as a systemic, policy-driven concern often gets lost in the din of every other news cycle, such as election cycles, market volatility, and geopolitical crises. At the very least, there is one day a year when 800 scientific institutions publish at the same time, government officials post messages, and researchers in Tasmania and Tanzania are ostensibly working toward the same goal. It is insufficient. Stand with science is the theme’s advice, and it’s a good one. Since the floor hasn’t been constructed yet, the more difficult question is who gets to stand and who is still seated.

The post World Health Day 2026: Why “Stand With Science” Is the Most Urgent Theme the WHO Has Ever Chosen appeared first on Creative Learning Guild.